Cipla has achieved a significant milestone with the U.S. Food and Drug Administration (USFDA) granting approval for its Abbreviated New Drug Application (ANDA) for the generic version of Advair Diskus® (fluticasone propionate and salmeterol inhalation powder). The approval covers all three strengths—100/50 mcg, 250/50 mcg, and 500/50 mcg—and allows Cipla to market a therapeutically equivalent alternative to one of the most widely prescribed inhaled combination therapies for asthma and chronic obstructive pulmonary disease (COPD).
Advair Diskus® combines an inhaled corticosteroid (ICS), fluticasone propionate, with the long-acting β2-agonist (LABA), salmeterol, providing effective long-term control of airway inflammation and bronchoconstriction. It is indicated for maintenance treatment of asthma in patients aged four years and older and for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with COPD. Generic availability of this therapy is expected to improve affordability and patient access while maintaining the same standards of quality, safety, and efficacy established by the reference product.
The approval reflects years of development by Cipla, including successful completion of a Phase III clinical study and submission of its ANDA for this complex inhalation product. The achievement further demonstrates the company’s expertise in developing technically challenging respiratory formulations and reinforces its commitment to expanding access to advanced inhalation therapies in regulated markets.
According to industry estimates, the U.S. market for Advair Diskus® and its generic equivalents is approximately US$908 million, highlighting the strategic importance of this approval. Analysts view the product as a key contributor to Cipla’s U.S. respiratory pipeline alongside other inhalation therapies under development or commercialization.
Overall, the USFDA approval strengthens Cipla’s position in the global respiratory segment and supports its long-term strategy of building a differentiated portfolio of complex generic products. By offering a cost-effective therapeutic equivalent for asthma and COPD management, Cipla is expected to enhance treatment accessibility while reinforcing its presence in the competitive U.S. pharmaceutical market.
